FIELD: chemical-pharmaceutical industry.
SUBSTANCE: invention refers to medical products and concerns method of human mammary gland cancer treatment including introduction of compound of formula 1 or its pharmaceutically acceptable salt where compound is introduced in amount within 5 to 20 mg per dose at dosage rate twice a day and where method additionally includes combined introduction of docetaxel. Besides, discovered is pancreas cancer treatment method including introduction of compound of formula 1 or its pharmaceutically acceptable salt in amount 5 to 20 mg per dose with dosage rate twice a day, thus method additionally includes combined introduction of hemcytabine.
EFFECT: provides considerable regress of tumour.
8 cl, 2 dwg, 4 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
ANTINEOPLASTIC AGENTS ERBB2 INTAKE SCHEME | 2004 |
|
RU2328287C2 |
INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
COMBINATIONS OF INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND CHEMIOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION | 2008 |
|
RU2523890C2 |
USE OF RAPAMYCIN DERIVATIVE | 2011 |
|
RU2483727C1 |
APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2659725C2 |
APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2665138C2 |
CANCER MEDICAL TREATMENT | 2005 |
|
RU2325906C2 |
COMBINATION AND METHOD FOR PROPHYLAXIS OF BREAST CANCER | 2002 |
|
RU2322981C2 |
THERAPEUTIC COMBINATIONS CONTAINING INHIBITOR OF POLY(ADP-RIBOSE)POLYMERASE | 2005 |
|
RU2361592C2 |
MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
Authors
Dates
2008-12-20—Published
2004-03-17—Filed